Thyroglobulin autoantibodies as surrogate biomarkers in the management of patients with differentiated thyroid carcinoma.

@article{FeldtRasmussen2014ThyroglobulinAA,
  title={Thyroglobulin autoantibodies as surrogate biomarkers in the management of patients with differentiated thyroid carcinoma.},
  author={Ulla Feldt-Rasmussen and Frederik Anton Verburg and Markus Luster and Cristina Cupini and Luca Chiovato and Leonidas H. Duntas and Rossella Elisei and Herald Rimmele and Ettore Seregni and Jan Smit and Christian Theimer and Luca Giovanella},
  journal={Current medicinal chemistry},
  year={2014},
  volume={21 32},
  pages={
          3687-92
        }
}
Differentiated thyroid cancer is a rare malignancy, but leaves numerous survivors for life-long follow-up. The cornerstone in current guidelines for follow-up is by measuring the thyroid specific tumour marker, thyroglobulin in serum. Most patients can be followed by this method, but some thyroid cancer patients have antithyroglobulin antibodies in serum, both at diagnosis and after treatment, where follow-up is commenced. These antibodies interfere technically in the immunological methods for… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations

Similar Papers

Loading similar papers…